NovoCure Limited (NVCR)
NVCR trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/0001645113-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NVCR on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | Jersey |
| IPO year | 2015 |
| SEC CIK | 0001645113 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $655.4M |
| Net income | -$136.2M |
| Operating income | -$153.8M |
| Net margin | -20.8% |
| Operating margin | -23.5% |
| Revenue growth | +8.3% |
| Cash | $93.5M |
| Total assets | $804.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $96.7M cash; operating cash flow -$181K a quarter. | Report 2026-09-30 |
| Shares outstanding | 116,915,959 (2026-10-23); 111,981,981 a year earlier; 106,861,113 three years earlier. | Cover page 2026-10-23 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kost Forer Gabbay & Kasierer, Tel Aviv, Israel | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $193.4M | -$10.4M | $22.7M | $96.7M | $25.0M | $725.4M | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $183.6M | -$15.7M | $8.1M | $93.7M | No debt tags | $699.2M | 10-Q 2026-07-23 |
| Q1 2026 2026-03-31 | $174.1M | -$71.1M | -$13.5M | $87.5M | No debt tags | $674.4M | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $174.3M | -$24.5M | -$18.0M | $93.5M | $195.0M | $655.4M | 10-Q 2026-10-29 |
| Q3 2025 2025-09-30 | $167.2M | -$37.3M | $20.6M | $342.1M | $560.6M | $642.3M | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $158.8M | -$40.1M | -$15.9M | $149.6M | $559.8M | $630.2M | 10-Q 2026-07-23 |
| Q1 2025 2025-03-31 | $155.0M | -$34.3M | -$35.7M | $127.3M | $559.0M | $621.7M | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $161.3M | -$65.9M | -$3.5M | $163.8M | $97.3M | $605.2M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-05-21 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.9% |
| 1 month | -17.3% |
| 3 months | -31.9% |
| Year to date | -8.5% |
| 1 year | +4.0% |
| From 52-week high | -40.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TNDM | Tandem Diabetes Care Inc. | $18.48 | -7.92% | $1.3B |
| PRCT | PROCEPT BioRobotics Corporation | $23.54 | -1.09% | $1.4B |
| DRTS | Alpha Tau Medical Ltd. | $11.97 | -10.54% | $1.1B |
| IART | Integra LifeSciences Holdings Corporation | $13.98 | -2.92% | $1.1B |
| IRMD | iRadimed Corporation | $84.84 | -0.60% | $1.1B |
| SGP | SpyGlass Pharma Inc. | $32.24 | -1.95% | $1.1B |
| SIBN | SI-BONE Inc. | $23.41 | -0.13% | $1.1B |
| ATEC | Alphatec Holdings Inc. | $6.78 | -4.10% | $1.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier